What is the 13F Pro Quality Score for SMTI?

13F Pro ranks Sanara MedTech Inc. (SMTI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SMTI's current score at https://13fpro.ai/research/SMTI (free sign-up required for the full ranking).

Where does 13F Pro source SMTI data?

All Sanara MedTech Inc. fundamentals and ownership data come directly from SEC EDGAR. Sanara MedTech Inc. files with the SEC under CIK 714256. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SMTI in?

Sanara MedTech Inc. (SMTI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SMTI research updated on 13F Pro?

SMTI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sanara MedTech Inc.(SMTI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 714256 SMTI stock profile & AI dashboard →

13F Pro Quality Score

29.7/100

Rank #2,391 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.9/100

Profitability

12.0/100

Balance Sheet

3.5/100

Earnings Quality

30.0/100

Free Cash Flow

25.2/100

Institutional Flow

11.6/100

Revenue Scale

17.8/100

Dilution Risk

25.7/100

SMTI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sanara MedTech Inc. (SMTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SMTI at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,391 of 2,879 stocks — the bottom half of the AI-ranked universe. SMTI scores in the top quartile across revenue growth (84.9). Areas of concern include balance sheet strength (3.5) and institutional flow (11.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Sanara MedTech Inc. reports quarterly revenue of $27.8M, net income of $459.0K, free cash flow of $-2.5M. Top institutional holders of SMTI by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Stonebridge Wealth Management,, based on the most recent SEC filings. SMTI trades on the Nasdaq exchange and files with the SEC under CIK 714256. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sanara MedTech Inc. directly from SEC EDGAR. Sanara MedTech Inc.'s 13F Pro composite quality score has ranged between 30 and 37 since 2023, currently 29.7 — a stable long-term trajectory across 19 quarterly and live scoring snapshots.

Revenue

Q1 2026

$27.8M

Net Income

Q1 2026

$459.0K

Free Cash Flow

Q1 2026

$-2.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+41.8% YoY

$65.0MFY 2023

FY20 $15.6MFY21 $24.1MFY22 $45.8MFY23 $65.0M

Net Income

+45.8% YoY

$-4.3MFY 2023

FY20 $-4.4MFY21 $-7.9MFY22 $-7.9MFY23 $-4.3M

Operating Income

+66.3% YoY

$-4.2MFY 2023

FY20 $-5.0MFY21 $-7.4MFY22 $-12.5MFY23 $-4.2M

EPS (Diluted)

+48.0% YoY

$-0.52FY 2023

FY20 $-0.76FY21 —FY22 $-1.00FY23 $-0.52

Total Assets

+21.0% YoY

$73.9MFY 2023

FY20 $9.8MFY21 $36.4MFY22 $61.0MFY23 $73.9M

Total Debt

$10.3MFY 2023

FY20 —FY21 —FY22 —FY23 $10.3M

Op. Cash Flow

+41.6% YoY

$-3.2MFY 2023

FY20 $-4.0MFY21 $-4.8MFY22 $-5.6MFY23 $-3.2M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$65.0M +41.8%	$45.8M +89.9%	$24.1M +54.9%	$15.6M +32.5%	$11.8M +86.6%	$6.3M
Net Income	$-4.3M +45.8%	$-7.9M -0.2%	$-7.9M -78.2%	$-4.4M -58.0%	$-2.8M -949.4%	$331.3K
Operating Income	$-4.2M +66.3%	$-12.5M -69.7%	$-7.4M -46.5%	$-5.0M -83.7%	$-2.7M -2375.0%	$120.4K
EPS (Diluted)	$-0.52 +48.0%	$-1.00	—	$-0.76 +42.4%	$-1.32	$0.00
Total Assets	$73.9M +21.0%	$61.0M +67.7%	$36.4M +270.4%	$9.8M -11.6%	$11.1M +401.3%	$2.2M
Total Debt	$10.3M	—	—	—	$0.00	—
Operating Cash Flow	$-3.2M +41.6%	$-5.6M -15.4%	$-4.8M -19.3%	$-4.0M -86.1%	$-2.2M -1449.7%	$-139.9K

AI Insight: SMTI Financial Trends

Revenue has grown from $20M to $28M over eight quarters, but equity has collapsed from $42M to $7M, signaling serious balance-sheet deterioration.

• Revenue grew 40% from $20M in Q2 2024 to $28M in Q1 2026, with growth stabilizing around $26–$28M over the last four quarters.

• Operating income turned positive at $3M in Q1 2026, recovering from a $6M loss in Q4 2024, suggesting gradual operational improvement.

• Total debt tripled from $15M in Q2 2024 to $46M in Q1 2026, while equity cratered from $42M to $7M over the same period.

• Operating cash flow turned negative at $-2M in Q1 2026, reversing the $4M generated in Q4 2025.

⚠ Equity collapsed from $40M in Q3 2024 to $6M in Q3 2025, likely driven by the $30M net loss — monitor goodwill impairment or write-downs.

⚠ Debt-to-equity ratio has surged to approximately 6.6x in Q1 2026 versus 0.4x in Q2 2024 — leverage is at a critical level.

⚠ Operating cash flow remains volatile and turned negative in Q1 2026 despite positive operating income — working capital dynamics warrant close scrutiny.

AI Insight: SMTI Ratio Trends

SMTI turned net profitable in Q1 2026 for the first time in at least eight quarters, but a D/E ratio of 6.58 signals the leverage cost of getting there.

• Net profit margin turned positive at 1.7% in Q1 2026, ending a streak of negative NPM dating back to at least Q2 2024.

• Operating margin improved from -8.9% in Q1 2025 to 9.5% in Q1 2026, a ~18pp year-over-year swing.

• ROE and ROA both turned positive in Q1 2026 at 26.1% and 2.6%, reversing deeply negative readings across prior quarters.

• D/E ratio surged from 0.79 in Q4 2024 to 7.74 in Q4 2025, remaining elevated at 6.58 in Q1 2026.

⚠ D/E at 6.58 is far above the 0.36–1.25 range seen through Q2 2025 — debt load now materially amplifies downside risk.

⚠ Operating margin has swung wildly quarter to quarter (-21.7% to +31.8%); Q1 2026's 9.5% may not represent a stable run-rate.

⚠ TTM NPM of -31.2% versus Q1 2026 quarterly NPM of +1.7% suggests prior quarters dragged heavily — watch for sustained profitability.

Get alerted when SMTI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sanara MedTech Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SMTI

BlackRock, Inc.
$3.9M228,767 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.6M151,367 sh
Stonebridge Wealth Management, LLC
$2.4M136,899 sh
ROYAL BANK OF CANADA
$2.3M131,389 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.5M85,662 sh
MARSHALL WACE, LLP
$1.3M76,282 sh
Squarepoint Ops LLC
$1.3M73,607 sh
RENAISSANCE TECHNOLOGIES LLC
$1.1M64,680 sh
STATE STREET CORP
$1.1M62,689 sh
AQR CAPITAL MANAGEMENT LLC
$686.1K39,938 sh

Fund	Value	Shares
BlackRock, Inc.	$3.9M	228,767
VANGUARD CAPITAL MANAGEMENT LLC	$2.6M	151,367
Stonebridge Wealth Management, LLC	$2.4M	136,899
ROYAL BANK OF CANADA	$2.3M	131,389
GEODE CAPITAL MANAGEMENT, LLC	$1.5M	85,662
MARSHALL WACE, LLP	$1.3M	76,282
Squarepoint Ops LLC	$1.3M	73,607
RENAISSANCE TECHNOLOGIES LLC	$1.1M	64,680
STATE STREET CORP	$1.1M	62,689
AQR CAPITAL MANAGEMENT LLC	$686.1K	39,938

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SMTI on your watchlist

Track score changes the day Sanara MedTech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SMTI a good stock to buy?

13F Pro's AI-powered analysis of Sanara MedTech Inc. (SMTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SMTI are available on the SMTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SMTI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SMTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sanara MedTech Inc.'s investment landscape.